摘要
目的观察胰激肽原酶加厄贝沙坦治疗2型糖尿病早期肾病的疗效。方法90例患者维持糖尿病原治疗方案不变,随机均分为两组,对照组口服厄贝沙坦,治疗组在此基础上加用胰激肽原酶。3个月后检测尿白蛋白排泄率变化。结果治疗组和对照组治疗后、各组治疗前后相比较,尿白蛋白排泄率变化有统计学意义(P<0.01)。结论胰激肽原酶加厄贝沙坦治疗早期糖尿病肾病,可有效减少患者微量白蛋白尿。
Objective To observe the efficacy of kallidinogenase plus irbesartan in treating the patients with early type 2 diabetic nephropathy（DN）. Methods 90 cases of early type 2 DN maintained the original diabetic treatment and were randomly divided into 2 groups. The control group took oral irbesartan,while on this basis the treatment group was added with kallidinogenase. The changes of urinary albumin excretion rate （UAER） were examined after 3 months. Results UAER had statistical differences between the treatment group and the control group and between before treatment and after treatment in each group（ P 〈 0.01 ）. Conclusion Kallidinogenase plus irbesartan in treatin~ early DN can effectively lessen microalbnminuria.
出处
《中国药业》
CAS
2013年第22期26-27,共2页
China Pharmaceuticals
